Reversal of Russian vaccine’Sputnik V’… “91.6% prevention effect, easy distribution”

-Russia’s new coronavirus infection (Corona 19) vaccine’Sputnik V’, which was the first in the world to be vaccinated without clinical trials, showed a 91.6% prevention rate, the vaccine developer said in a thesis on the 2nd. Pfizer’s vaccine has a 95% prevention rate, Modena’s 94.1%, and Janssen’s 66%.

Researchers at the Gamalea National Center for Infectious Diseases and Microbiology under the Ministry of Health of Russia, who developed the Sputnik V vaccine, said, “Two vaccination trials were conducted on 11,868 people in a paper on the results of a phase 3 clinical trial published in the international medical journal’Lancet’. As a result, the effect appeared like this.” Russia approved the urgent use of this vaccine for the first time in the world in August of last year, and a phase 3 clinical study has been conducted at the same time as the vaccination in September.

It has been criticized for safety concerns because of the unusual approval, but according to the paper, there were no serious side effects related to the vaccine. The vaccine should be stored at -18 degrees Celsius, but the storage of images 2-8 degrees for easy distribution has also been approved by the Ministry of Health of Russia, the thesis said. The international market price of the vaccine is about 20 dollars (about 23,000 won).

‘Love call’ is also continuing. German Chancellor Angela Merkel said in an interview with German broadcaster ARD on the 2nd that “I have read good data on Russian vaccines.” French President Emmanuel Macron also said on the same day that “a few weeks ago, I had a scientific investigation into the Sputnik V vaccine, and I received a positive answer.” As Mexico urgently approved the use of the vaccine on the 2nd, the number of countries approved for use increased to 17 countries around the world. Gelapa, a domestic biotechnology company, is consigning production of some of this vaccine for export. The University of Oxford, which jointly developed the AstraZeneca vaccine, said on the 1st (local time) that “this vaccine can be administered twice every three months for a wide range of vaccinations under limited quantities of the vaccine.” With just one vaccination, the antibody was retained to some extent from 22 days to 90 days after vaccination, showing an average of 76% of preventing’symptomatic infections’, and the second vaccination after 12 weeks increased the prevention effect to 82.4%. I went.

Reporter Jo Jung-yeop [email protected]